Earnings summaries and quarterly performance for LEXICON PHARMACEUTICALS.
Executive leadership at LEXICON PHARMACEUTICALS.
Michael Exton
Detailed
Chief Executive Officer
CEO
AM
Alan Main
Detailed
Executive Vice President, Innovation and Chemical Sciences
BC
Brian Crum
Detailed
Senior Vice President and General Counsel
CG
Craig Granowitz
Detailed
Senior Vice President and Chief Medical Officer
KA
Kristen Alexander
Detailed
Vice President, Finance and Accounting
Board of directors at LEXICON PHARMACEUTICALS.
Research analysts who have asked questions during LEXICON PHARMACEUTICALS earnings calls.
Joseph Pantginis
H.C. Wainwright & Co.
3 questions for LXRX
Also covers: ARMP, BCDA, BLRX +15 more
YR
Yasmeen Rahimi
Piper Sandler & Co.
3 questions for LXRX
Also covers: ALT, ARCT, CRNX +12 more
Andrew Tsai
Jefferies
2 questions for LXRX
Also covers: ARQT, ATAI, ATHA +13 more
Joseph Stringer
Needham & Company
2 questions for LXRX
Also covers: APLS, CDTX, PCVX +3 more
Linda Tsai
Jefferies
2 questions for LXRX
Also covers: ADC, AKR, AMH +31 more
RR
Roanna Ruiz
Leerink
2 questions for LXRX
Also covers: CRMD, ENTA, UTHR
YN
Yigal Nochomovitz
Citigroup Inc.
2 questions for LXRX
Also covers: ALDX, APLS, ARCT +22 more
Caroline DePaul
Citigroup Inc.
1 question for LXRX
Liam Hiester
Piper Sandler
1 question for LXRX
Also covers: VTYX
Mazahir Alimohamed
Leerink Partners
1 question for LXRX
Also covers: AKBA, AMRN, AQST +2 more
Recent press releases and 8-K filings for LXRX.
Lexicon Pharmaceuticals Closes Public Offering and Private Placement
LXRX
Convertible Preferred Issuance
New Projects/Investments
- Lexicon Pharmaceuticals, Inc. (LXRX) announced the closing of its previously announced underwritten public offering and concurrent private placement on February 2, 2026.
- The public offering involved 32,000,000 shares of common stock sold at $1.30 per share.
- The concurrent private placement included 22,400,000 shares of common stock and 367,145 shares of Series B Convertible Preferred Stock sold at $65 per share.
- Lexicon intends to use the net proceeds to fund the continued research and development of its drug candidates and for working capital and other general corporate purposes.
7 hours ago
Lexicon Pharmaceuticals Announces $94.6 Million Public Offering and Private Placement
LXRX
Convertible Preferred Issuance
New Projects/Investments
- Lexicon Pharmaceuticals, Inc. announced the pricing of a public offering of 32,000,000 shares of common stock at $1.30 per share, expected to generate $41.6 million in gross proceeds.
- Concurrently, the company is conducting a private placement with affiliates of Invus, L.P., its largest stockholder, for expected aggregate gross proceeds of approximately $41.1 million.
- This private placement includes the sale of 22,400,000 shares of common stock at $1.30 per share and 367,145.12 shares of Series B Convertible Preferred Stock at $65.00 per share, with each preferred share convertible into 50 shares of common stock.
- The total expected gross proceeds from both the public offering and concurrent private placement are approximately $94.6 million, which will be used for continued research and development and general corporate purposes.
- Following these transactions, the Invus Entities are projected to own approximately 51% of Lexicon's outstanding Common Stock.
4 days ago
Lexicon Pharmaceuticals Announces Pricing of Public Offering and Concurrent Private Placement
LXRX
Convertible Preferred Issuance
- Lexicon Pharmaceuticals announced the pricing of an underwritten public offering of 32,000,000 shares of common stock at $1.30 per share, expected to generate $41.6 million in gross proceeds.
- Concurrently, Lexicon agreed to a private placement with an affiliate of Invus, L.P., its largest stockholder, for expected aggregate gross proceeds of approximately $41.1 million from the sale of common stock and Series B Convertible Preferred Stock.
- The private placement purchaser also committed to an additional purchase of Series B Convertible Preferred Stock for approximately $11.9 million.
- The total expected gross proceeds from both the public offering and concurrent private placement are approximately $94.6 million.
- Lexicon intends to use the net proceeds to fund continued research and development of its drug candidates, as well as for working capital and other general corporate purposes.
8 days ago
Lexicon Announces Proposed Public Offering of Common Stock and Provides Business Updates
LXRX
New Projects/Investments
Guidance Update
- Lexicon Pharmaceuticals, Inc. announced a proposed underwritten public offering of common stock and a concurrent private placement to an affiliate of Invus, L.P., its largest stockholder.
- The net proceeds from the offering are intended to fund continued research and development of drug candidates and for working capital and other general corporate purposes.
- The company ended 2025 with an unaudited $125.2 million in cash, investments, and restricted cash, which is expected to support planned operations into 2027.
- Lexicon also provided updates on its pipeline, including anticipated topline results for the SONATA-HCM study in Q1 2027 and a potential NDA resubmission for ZYNQUISTA® in 2026.
Jan 29, 2026, 9:37 PM
Lexicon Pharmaceuticals Announces Proposed Public Offering and Private Placement
LXRX
- Lexicon Pharmaceuticals has commenced an underwritten public offering of its common stock and intends to grant the underwriters a 30-day option to purchase additional shares.
- Concurrently, Lexicon plans to sell shares of its common stock in a private placement to an affiliate of Invus, L.P., its largest stockholder, exercising its preemptive right.
- The company intends to use the net proceeds from the proposed offering to fund the continued research and development of its drug candidates and for working capital and other general corporate purposes.
- Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.
Jan 29, 2026, 9:31 PM
Lexicon Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA for Pilavapadin
LXRX
New Projects/Investments
- Lexicon Pharmaceuticals, Inc. announced the successful completion of its End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP).
- The FDA raised no objections to advancing pilavapadin into Phase 3 development, which will include two placebo-controlled, 12-week, two-arm registrational studies.
- Pilavapadin is an investigational non-opioid small molecule inhibitor of AAK1, with the goal of making the first non-opioid DPNP medicine available to patients in over two decades.
Jan 21, 2026, 1:30 PM
Lexicon Pharmaceuticals Updates on Pipeline Progress and Financial Position at J.P. Morgan Conference
LXRX
New Projects/Investments
Guidance Update
Product Launch
- Lexicon Pharmaceuticals is advancing its late-stage pipeline, with the SONATA Phase 3 trial for hypertrophic cardiomyopathy (HCM) expected to conclude enrollment in H1 2026 and deliver top-line data in Q1 2027.
- The company is on track for a potential resubmission and approval of Zynquista for type 1 diabetes (T1D) in 2026, following alignment with the FDA on using investigator data from the Steno 1 study.
- Lexicon plans to advance Pivapladin for neuropathic pain into Phase 3 clinical trials in 2026 and is actively seeking partners for its development.
- Financially, Lexicon ended 2025 with approximately $125 million in cash and cash equivalents, providing an operational runway into 2027. The company also received a $10 million milestone payment from Novo Nordisk for LX9851 and expects an additional $20 million in 2026.
Jan 15, 2026, 8:00 PM
Lexicon Pharmaceuticals Provides Updates on Financials, Product Pipeline, and Partnerships
LXRX
Guidance Update
New Projects/Investments
Product Launch
- Lexicon Pharmaceuticals reported preliminary Full Year 2025 financials, ending the year with $125.2 million in cash, investments, and restricted cash, which is sufficient to support planned operations into 2027.
- The company is advancing key late-stage programs, including the SONATA-HCM Phase 3 study for sotagliflozin, with topline results anticipated in Q1 2027, and a planned 2026 resubmission of the New Drug Application for Zynquista (sotagliflozin) in Type 1 Diabetes.
- Partnership efforts include a $10 million milestone payment received in January 2026 from Novo Nordisk for LX9851, with potential for an additional $20 million in 2026, and ongoing discussions for pilavapadin following anticipated FDA feedback in January 2026.
- International expansion for sotagliflozin (INPEFA) is underway, with recent approval in UAE and ongoing regulatory submissions in countries such as Saudi Arabia, Canada, Australia, New Zealand, Mexico, and Malaysia.
Jan 15, 2026, 8:00 PM
Lexicon Pharmaceuticals Provides Pipeline and Financial Update at J.P. Morgan Healthcare Conference
LXRX
Product Launch
New Projects/Investments
Guidance Update
- Lexicon Pharmaceuticals is advancing its late-stage pipeline, including sotagliflozin (INPEFA) in Phase 3 for hypertrophic cardiomyopathy (SONATA trial), with enrollment concluding in the first half of 2026 and top-line data expected in the first quarter of 2027.
- The company is on track for a potential 2026 resubmission and approval of Zynquista (sotagliflozin) for type 1 diabetes, following alignment with the FDA on using third-party investigator data.
- Pivapladin, a non-opioid treatment for neuropathic pain, is being prepared for Phase 3 clinical trials in 2026, with Lexicon engaging potential partners.
- Lexicon secured an exclusive worldwide license for LX9851 with Novo Nordisk, which triggered a $10 million milestone payment and is expected to generate another $20 million in 2026. The company reported $125 million in cash and cash equivalents at the end of 2025, supporting operations into 2027.
Jan 15, 2026, 8:00 PM
Lexicon Pharmaceuticals Discusses Pipeline Progress and Financial Position at J.P. Morgan Healthcare Conference
LXRX
Product Launch
New Projects/Investments
Guidance Update
- Lexicon Pharmaceuticals is focused on cardiometabolic disease and pain, with a pipeline including INPEFA for heart failure, Zynquista for type 1 diabetes, pilavapadin for neuropathic pain, and LX9851 for obesity.
- The company expects to conclude enrollment for the Phase III SONATA trial for hypertrophic cardiomyopathy (HCM) in the first half of 2026, with potential top-line data in the first quarter of 2027.
- Lexicon is on track for a potential resubmission and approval of Zynquista for type 1 diabetes in 2026, based on investigator data from the Steno-1 study.
- Pilavapadin is set to enter Phase III clinical trials in 2026 for neuropathic pain, with the company actively seeking partners.
- Lexicon licensed LX9851 to Novo Nordisk, triggering a $10 million milestone payment, with another $20 million payment expected in 2026. The company ended 2025 with approximately $125 million in cash and cash equivalents, supporting operations into 2027.
Jan 15, 2026, 8:00 PM
Quarterly earnings call transcripts for LEXICON PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more